Risk factors
InMed Pharmaceuticals (INM) risk factors
Item 1A of every InMed Pharmaceuticals Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2026 10-K risk factors78 risks5 new2 reworded
Merger execution, litigation, and failure to complete the transaction now dominate the risk disclosures.
Filed Sep 09, 2026 - FY2025 10-K risk factors73 risks2 new5 dropped8 reworded
New U.S. tariffs and global trade conflicts create macroeconomic uncertainty for operations.
Filed Sep 23, 2025 - FY2024 10-K risk factors76 risks
InMed Pharmaceuticals faces early-stage clinical trial risks and Nasdaq delisting threats due to minimum bid price requirements. The company relies heavily on its proprietary IntegraSyn manufacturing approach and EB disease indications. Regulatory approval processes across the FDA, HC, and EMA remain lengthy and uncertain.
Filed Sep 30, 2024